{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012133","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.855014+00:00","generated_at":"2026-05-31T09:13:31.711920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protalix Q2 2024: revenue $13.5M, net loss $2.2M; PRX-115 Phase I topline expected Q3","bullets":["Total Q2 2024 revenue $13.5M vs $35.1M in Q2 2023; net loss $2.2M ($0.03/sh) vs net income $19.3M ($0.29/sh).","Product revenue from goods $13.3M (-12% YoY); license & R&D revenue $0.2M (vs $20.0M milestone from Chiesi in Q2 2023).","PRX-115 (uncontrolled gout) Phase I: positive topline from first 7 cohorts; 8th cohort dosed, full results expected Q3 2024.","Cash, cash equivalents and short-term bank deposits $45.0M at June 30, 2024; post-quarter collected $4.6M from Pfizer, $2.3M from Brazil.","R&D expenses decreased 33% to $3.0M due to completion of Fabry clinical program and Elfabrio regulatory processes."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012133","json":"https://secwatch.observer/filing/0001558370-24-012133.json","markdown":"https://secwatch.observer/filing/0001558370-24-012133.md","text":"https://secwatch.observer/filing/0001558370-24-012133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024012133/0001558370-24-012133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024012133/plx-20240814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:13:31.711920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}